Literature DB >> 9930052

Intracoronary Multi-link stents: experience in 218 patients using aspirin alone.

A L Calver1, K D Dawkins, H H Gray, G A Haywood, J M Morgan, I A Simpson.   

Abstract

OBJECTIVES: To assess procedural outcome, complications, and clinical follow up in 218 patients who underwent treatment with 297 Multi-link (Guidant) stents implanted without the use of intravascular ultrasound (IVUS) or quantitative coronary angiography (QCA), and using aspirin alone as antiplatelet therapy.
METHODS: The case records and angiograms were reviewed and the patients were contacted by telephone to determine their symptoms and any adverse events at follow up. Data were analysed using Fisher's exact test.
RESULTS: Of the 218 patients included in the study, 45 had multivessel intracoronary intervention, and 55 had unstable angina. The mean (SD) length of hospital stay following the procedure was 2.0 (2.1) days. There were two early deaths at less than 30 days, and two deaths during follow up at more than 100 days. Ten patients suffered complications during the first 30 days: four had subacute stent thrombosis, of whom two died and two were treated successfully with coronary artery bypass grafting; five had a non-Q wave myocardial infarction; and one had a femoral false aneurysm. Patient outcome was analysed according to stent diameter (3.0 mm or less, or 3.5 mm or more) and by angina status (stable or unstable). In patients in whom at least one stent was 3.0 mm diameter, four of 86 patients suffered acute stent occlusion, whereas in the 132 patients in whom all stents were at least 3.5 mm diameter there were no cases of stent occlusion (p = 0.02). In the unstable angina group two of 55 patients suffered acute stent occlusion compared to two of 163 patients in the stable angina group (NS). In patients with unstable angina and at least one stent of 3.0 mm diameter, the acute occlusion rate was 7.1% (two of 28 patients). Three of the four patients with stent occlusion had undergone complex procedures. Twenty eight patients were restudied for recurrent symptoms during the follow up period. Of these, eight patients had restenosis within their stent. In seven of these patients the stent size was 3.0 mm diameter, and in the remaining patient the stent size was 4.0 mm diameter. Three of the 28 patients restudied had developed new disease remote from the stented site, and 17 had patent stents and no significant other coronary lesion.
CONCLUSIONS: This study suggests that coronary intervention using the Multi-link stent is safe and effective using aspirin alone, without IVUS or QCA, when stent diameter is greater than 3.0 mm. All cases of stent occlusion in this series occurred in patients in whom at least one stent was 3.0 mm diameter, with stent occlusion being higher in patients with unstable angina compared to those with stable angina. Additional antiplatelet therapy may be beneficial in those patients in whom Multi-link stent diameter is less than 3.5 mm, particularly in those with unstable angina, but is not necessary for patients receiving Multi-link stents of 3.5 mm diameter or greater.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9930052      PMCID: PMC1728838          DOI: 10.1136/hrt.80.5.499

Source DB:  PubMed          Journal:  Heart        ISSN: 1355-6037            Impact factor:   5.994


  16 in total

1.  Endovascular stent design dictates experimental restenosis and thrombosis.

Authors:  C Rogers; E R Edelman
Journal:  Circulation       Date:  1995-06-15       Impact factor: 29.690

2.  AHA president's letter.

Authors:  S C Smith
Journal:  Circulation       Date:  1995-07-01       Impact factor: 29.690

3.  A comparison of balloon-expandable-stent implantation with balloon angioplasty in patients with coronary artery disease. Benestent Study Group.

Authors:  P W Serruys; P de Jaegere; F Kiemeneij; C Macaya; W Rutsch; G Heyndrickx; H Emanuelsson; J Marco; V Legrand; P Materne
Journal:  N Engl J Med       Date:  1994-08-25       Impact factor: 91.245

4.  Intracoronary stenting for acute and threatened closure complicating percutaneous transluminal coronary angioplasty.

Authors:  G S Roubin; A D Cannon; S K Agrawal; P J Macander; L S Dean; W A Baxley; J Breland
Journal:  Circulation       Date:  1992-03       Impact factor: 29.690

5.  A randomized comparison of coronary-stent placement and balloon angioplasty in the treatment of coronary artery disease. Stent Restenosis Study Investigators.

Authors:  D L Fischman; M B Leon; D S Baim; R A Schatz; M P Savage; I Penn; K Detre; L Veltri; D Ricci; M Nobuyoshi
Journal:  N Engl J Med       Date:  1994-08-25       Impact factor: 91.245

6.  Long-term angiographic and clinical outcome after implantation of a balloon-expandable stent in the native coronary circulation. Palmaz-Schatz Stent Study Group.

Authors:  M P Savage; D L Fischman; R A Schatz; P S Teirstein; M B Leon; D Baim; S G Ellis; E J Topol; J W Hirshfeld; M W Cleman
Journal:  J Am Coll Cardiol       Date:  1994-11-01       Impact factor: 24.094

7.  Changing incidence and management of abrupt closure following coronary intervention in the new device era.

Authors:  R E Kuntz; R Piana; R M Pomerantz; J Carrozza; R Fishman; M Mansour; R D Safian; D S Baim
Journal:  Cathet Cardiovasc Diagn       Date:  1992-11

8.  Intravascular stents to prevent occlusion and restenosis after transluminal angioplasty.

Authors:  U Sigwart; J Puel; V Mirkovitch; F Joffre; L Kappenberger
Journal:  N Engl J Med       Date:  1987-03-19       Impact factor: 91.245

9.  Intracoronary stenting without anticoagulation accomplished with intravascular ultrasound guidance.

Authors:  A Colombo; P Hall; S Nakamura; Y Almagor; L Maiello; G Martini; A Gaglione; S L Goldberg; J M Tobis
Journal:  Circulation       Date:  1995-03-15       Impact factor: 29.690

10.  Acute coronary artery occlusion during and after percutaneous transluminal coronary angioplasty. Frequency, prediction, clinical course, management, and follow-up.

Authors:  P J de Feyter; M van den Brand; G J Laarman; R van Domburg; P W Serruys; H Suryapranata; G Jaarman
Journal:  Circulation       Date:  1991-03       Impact factor: 29.690

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.